Table 2.
Synergistic antitumor activity of combining sunitinib (S), dasatinib (D) with MK-2206 (M) in ovarian cancer cells.
| Cell | Combination | Fold Reduction (IC50) | Fold Reduction (IC75) | CI | |||||
|---|---|---|---|---|---|---|---|---|---|
| S | D | M | S | D | M | ED50 | ED75 | ||
| MDAH2774 | SM (1:5) | 1.58 | NA | 7.79 | 1.05 | NA | 37.32 | 0.76 | 0.97 |
| DM (1:50) | NA | 8.43 | 37.9 | NA | 37.44 | 26.35 | 0.18 | 0.06 | |
| SD (10:1) | 4.21 | 9.56 | NA | 2.19 | 110.49 | NA | 0.34 | 0.46 | |
| SDM (10:1:50) | 6.83 | 15.51 | 33.68 | 3.71 | 186.76 | 131.44 | 0.24 | 0.28 | |
| SKOV3 | SM (1:1) | 5.04 | NA | 3.76 | 6.98 | NA | 26.22 | 0.46 | 0.18 |
| DM (1:10) | 4.62 | 4.40 | NA | NA | 24.56 | 17.68 | 0.44 | 0.10 | |
| SD (10:1) | 3.26 | 2.3 | NA | 2.95 | 15.37 | NA | 0.74 | 0.40 | |
| SDM (10:1:10) | 7.9 | 5.6 | 5.92 | 10.91 | 56.84 | 40.95 | 0.47 | 0.13 | |
IC50 and IC75: concentrations giving 50% and 75% inhibition; ED50 and 75: effective doses giving 50% and 75% inhibition; CI: combination index. S: sunitinib; D: dasatinib; M: MK-2206.